Mexico beats France in this year's ETF face-off, but long-term risks could flip the outcome. Who wins the market war?
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1Mature overall survival data builds on encouraging high response rates with multiple complete responsesPatients with CPS <1 represent a high unmet medical need and have no available treatment options without chemotherapyMeeting with FDA has now been requested to discuss next steps including potential paths to approval SYDNEY, AUSTRALIA, May 05,
SCOTTSDALE, Ariz., May 05, 2025--onsemi (the "Company") (Nasdaq: ON) today announced its first quarter 2025 results with the following highlights:
Howard Hughes Holdings said Bill Ackman’s Pershing Square Capital Management will invest $900 million in the company, boosting its stake further and bringing Ackman back into the fold.
Over the first four months of 2025, sales of Teslas in Spain fell 17% over the same period a year earlier, while sales of electrified vehicles, a category that includes both fully electric vehicles and hybrids, were up 54%. Sales of Teslas have dropped in Europe as the manufacturer owned by billionaire Elon Musk faces increased competition from European and especially Chinese EV brands.
SPRINGDALE, Ark. AP) — Tyson Foods Inc. TSN) on Monday reported fiscal second-quarter earnings of $7 million.
Below, we share with you three large-cap blend mutual funds, viz., FLCSX, VQNPX and DFUEX. Each has earned a Zacks Mutual Fund #1 Rank.
Meat company Tyson Foods (NYSE:TSN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $13.07 billion. Its non-GAAP profit of $0.92 per share was 12.2% above analysts’ consensus estimates.
Recent advancements in the biotechnology sector highlight a significant development with RetinalGenix Technologies, Inc. leasing a laboratory at the MBC BioLabs incubator in San Carlos, California. This strategic move is set to support the progress of RetinalGenix's innovative Pharmaco-Genetic Mapping platform, aimed at advancing therapies for neurodegenerative and retinal diseases. The facility offers access to cutting-edge scientific equipment and is conveniently located near resources...
Tesla's new model will likely be a scaled-down version of the current model it already produces. Management says the new EV will be "affordable" and that production will begin in June. Tesla (NASDAQ: TSLA) has been talking about a cheaper EV for years, but it has always been just out of reach, and plans to build one have continually changed.